SYI2_STAAU
ID SYI2_STAAU Reviewed; 1024 AA.
AC P41368;
DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1995, sequence version 1.
DT 03-AUG-2022, entry version 125.
DE RecName: Full=Isoleucine--tRNA ligase;
DE EC=6.1.1.5;
DE AltName: Full=Isoleucyl-tRNA synthetase;
DE Short=IleRS;
GN Name=ileS; Synonyms=mupR;
OS Staphylococcus aureus.
OG Plasmid pOX301.
OC Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae;
OC Staphylococcus.
OX NCBI_TaxID=1280;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RC STRAIN=J2870; PLASMID=pOX301;
RX PubMed=8067768; DOI=10.1128/aac.38.5.1205;
RA Hodgson J.E., Curnock S.P., Dyke K.G.H., Morris R., Sylvester D.R.,
RA Gross M.S.;
RT "Molecular characterization of the gene encoding high-level mupirocin
RT resistance in Staphylococcus aureus J2870.";
RL Antimicrob. Agents Chemother. 38:1205-1208(1994).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 504-519 AND 550-609, AND FUNCTION.
RC STRAIN=J2870;
RX PubMed=1903747; DOI=10.1016/0378-1097(91)90550-t;
RA Dyke K.G.H., Curnock S.P., Golding M., Noble W.C.;
RT "Cloning of the gene conferring resistance to mupirocin in Staphylococcus
RT aureus.";
RL FEMS Microbiol. Lett. 61:195-198(1991).
CC -!- FUNCTION: Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS
CC can inadvertently accommodate and process structurally similar amino
CC acids such as valine, to avoid such errors it has two additional
CC distinct tRNA(Ile)-dependent editing activities. One activity is
CC designated as 'pretransfer' editing and involves the hydrolysis of
CC activated Val-AMP. The other activity is designated 'posttransfer'
CC editing and involves deacylation of mischarged Val-tRNA(Ile) (By
CC similarity). {ECO:0000250}.
CC -!- FUNCTION: Confers high-level resistance to the antibiotic mupirocin
CC (pseudomonic acid A), an Ile-analog that competitively inhibits
CC activation by Ile-tRNA synthetase, thus inhibiting protein
CC biosynthesis. {ECO:0000269|PubMed:1903747, ECO:0000269|PubMed:8067768}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + L-isoleucine + tRNA(Ile) = AMP + diphosphate + L-
CC isoleucyl-tRNA(Ile); Xref=Rhea:RHEA:11060, Rhea:RHEA-COMP:9666,
CC Rhea:RHEA-COMP:9695, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC ChEBI:CHEBI:58045, ChEBI:CHEBI:78442, ChEBI:CHEBI:78528,
CC ChEBI:CHEBI:456215; EC=6.1.1.5;
CC -!- COFACTOR:
CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC -!- SUBUNIT: Monomer. {ECO:0000250}.
CC -!- SUBCELLULAR LOCATION: Cytoplasm.
CC -!- DOMAIN: IleRS has two distinct active sites: one for aminoacylation and
CC one for editing. The misactivated valine is translocated from the
CC active site to the editing site, which sterically excludes the
CC correctly activated isoleucine. The single editing site contains two
CC valyl binding pockets, one specific for each substrate (Val-AMP or Val-
CC tRNA(Ile)) (By similarity). {ECO:0000250}.
CC -!- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase family.
CC IleS type 2 subfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; X75439; CAA53189.1; -; Genomic_DNA.
DR EMBL; X59478; CAA42080.1; -; Genomic_DNA.
DR EMBL; X59477; CAA42079.1; -; Genomic_DNA.
DR RefSeq; WP_012263521.1; NG_056478.1.
DR RefSeq; YP_001653102.1; NC_010279.1.
DR AlphaFoldDB; P41368; -.
DR SMR; P41368; -.
DR PRIDE; P41368; -.
DR BRENDA; 6.1.1.5; 3352.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0002161; F:aminoacyl-tRNA editing activity; IEA:InterPro.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR GO; GO:0004822; F:isoleucine-tRNA ligase activity; IEA:UniProtKB-UniRule.
DR GO; GO:0000049; F:tRNA binding; IEA:InterPro.
DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule.
DR GO; GO:0006428; P:isoleucyl-tRNA aminoacylation; IEA:UniProtKB-UniRule.
DR GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR CDD; cd07961; Anticodon_Ia_Ile_ABEc; 1.
DR Gene3D; 3.40.50.620; -; 2.
DR HAMAP; MF_02003; Ile_tRNA_synth_type2; 1.
DR InterPro; IPR001412; aa-tRNA-synth_I_CS.
DR InterPro; IPR002300; aa-tRNA-synth_Ia.
DR InterPro; IPR033709; Anticodon_Ile_ABEc.
DR InterPro; IPR002301; Ile-tRNA-ligase.
DR InterPro; IPR023586; Ile-tRNA-ligase_type2.
DR InterPro; IPR013155; M/V/L/I-tRNA-synth_anticd-bd.
DR InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR InterPro; IPR009080; tRNAsynth_Ia_anticodon-bd.
DR InterPro; IPR009008; Val/Leu/Ile-tRNA-synth_edit.
DR PANTHER; PTHR42780; PTHR42780; 1.
DR Pfam; PF08264; Anticodon_1; 1.
DR Pfam; PF00133; tRNA-synt_1; 1.
DR PRINTS; PR00984; TRNASYNTHILE.
DR SUPFAM; SSF47323; SSF47323; 2.
DR SUPFAM; SSF50677; SSF50677; 1.
DR TIGRFAMs; TIGR00392; ileS; 1.
DR PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
PE 3: Inferred from homology;
KW Aminoacyl-tRNA synthetase; Antibiotic resistance; ATP-binding; Cytoplasm;
KW Ligase; Metal-binding; Nucleotide-binding; Plasmid; Protein biosynthesis;
KW Zinc.
FT CHAIN 1..1024
FT /note="Isoleucine--tRNA ligase"
FT /id="PRO_0000098562"
FT MOTIF 42..52
FT /note="'HIGH' region"
FT MOTIF 585..589
FT /note="'KMSKS' region"
FT BINDING 588
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250"
FT CONFLICT 519
FT /note="P -> R (in Ref. 2; CAA42079)"
FT /evidence="ECO:0000305"
FT CONFLICT 591..593
FT /note="GNV -> ETF (in Ref. 2; CAA42080)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 1024 AA; 118876 MW; 56ECD232CA0C8430 CRC64;
MTKKYLNTQN EISAFWNTQK IFKKSIDNRK GQESFVFYDG PPTANGLPHA GHVLGRVIKD
LVARLKTMQG FYVERKAGWD THGLPVELEV EKKIGIKGKQ DIEKYGIENF INECKKSVFN
YEKEWRDFSK DLGYWVDMDS PYITLENNYI ESVWNILSTF HKKGLLYKGH KVTPYCTHDQ
TALSSHEVAQ GYKNVKDLSA VVKFQLTNSK DTYFLSWTTT PWTLPANVAL AINKDLNYSK
IRVENEYYIL ATDLINSIIT EKYEIIDTFS GSNLINLKYI PPFESDGLVN AYYVVDGEFV
TNSEGTGIVH IAPAHGEDDY QLVLERDLDF LNVITREGVY NDRFPELVGN KAKNSDIEII
KLLSKKQLLY KKQKYEHNYP HCWRCGNPLI YYAMEGWFIK TTNFKNEIIN NNNNIEWFPS
HIKEGRMGNF LENMVDWNIG RNRYWGTPLN VWICNDCNHE YAPSSIKDLQ NNSINKIDED
IELHRPYVDN ITLSCPKCNG KMSRVEEVID VWFDSGSMPF AQHHYPFDNQ KIFNQHFPAD
FIAEGVDQTR GWFYSLLVIS TILKGKSSYK RALSLGHILD SNGKKMSKSK GNVINPTELI
NKYGADSLRW ALISDSAPWN NKRFSENIVA QTKSKFIDTL DNIYKFYNMY NKIDHYNPNN
EITKSRNTLD NWALSRLNTL IKESNIYVNN YDFTSAARLI NEYTNTISNW YIGDSRGRFW
EQGISNDKKD AYNTLYEILT TLSRLVAPFV PFISEKIHYN LTGKSVHLQD YPQYKESFIN
QALEDEMHTV IKIVELSRQA RKNADLKIKQ PLSKMVIKPN SQLNLSFLPN YYSIIKDELN
IKNIELTDNI NDYITYELKL NFSSVGPKLG NKTKNIQTLI DSLSEYDKKS LIESNNFKSL
SSDAELTKDD FIIKTLPKDS YQLSEDNDCV ILLDKNLSPE LIREGHAREL IRLIQQLRKK
KNLPINQRID IYIGVTGELL ESIKTNKNMF KENFVIKNIH LNVIDEYENT IHFNNKEIKI
SLLY